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Hematopoietic stem cells (HSCs) can both 
self-renew and differentiate to all blood cells 
(Spangrude et al., 1988) and are found in 
LinSca1+Kit+ (LSK) fraction of BM cells. 
Generation of lymphocytes from HSCs is a 
stepwise process through multiple progenitors, 
including multipotent progenitors (MPPs), 
lymphoid-primed MPPs (LMPPs; Adolfsson 
et al., 2005), and common lymphoid progen-
itors (CLPs; Kondo et al., 1997). In the LSK 
compartment, MPPs and LMPPs have increased 
expression of the transmembrane receptor fms-
like tyrosine kinase 3 (Flt3; Adolfsson et al., 2005), 
which is associated with progressive loss of 
potential to megakaryocyte-erythroid progeni-
tors (MEPs; Adolfsson et al., 2005; Månsson 
et al., 2007). Two transcription factors, Pu.1 and 
Ikaros, are important for lymphoid lineage de-
velopment in LMPPs (Yoshida et al., 2006; 
Ng et al., 2009; Carotta et al., 2010).
In the adult mouse, lymphocyte develop-
ment from early progenitors occurs primarily 
in the BM for B cells or in the thymus for 
T cells. B cell development requires the in-
terplay of transcription factors and external 
cues of the microenvironment (Nutt and Kee, 
2007). Specification of the B cell lineage pro-
gram and loss of alternative lineage potential 
require a network of transcription factors, 
including E2A (Tcf3), Ebf1, Pax5, and Foxo1 
(Lin et al., 2010; Mandel and Grosschedl, 
2010). E2A proteins are implicated at multi-
ple stages of B cell development (Bain et al., 
1994; Zhuang et al., 1994; Kwon et al., 2008) 
and have functions in LMPPs, early T cell pro-
genitors (ETPs), and lineage priming (Dias et al., 
2008). Deletion of Ebf1, Foxo1, and Pax5 also 
blocks early B cell development (Urbanek et al., 
1994; Lin and Grosschedl, 1995; Dengler et al., 
2008). Additional key regulators in B cell de-
velopment include Myb, Lrf1, Miz1, Foxp1, 
and Mysm1 (Hu et al., 2006; Maeda et al., 
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Transcription factors play important roles in lymphopoiesis. We have previously demon-
strated that Bcl11a is essential for normal lymphocyte development in the mouse embryo. 
We report here that, in the adult mouse, Bcl11a is expressed in most hematopoietic cells 
and is highly enriched in B cells, early T cell progenitors, common lymphoid progenitors 
(CLPs), and hematopoietic stem cells (HSCs). In the adult mouse, Bcl11a deletion causes 
apoptosis in early B cells and CLPs and completely abolishes the lymphoid development 
potential of HSCs to B, T, and NK cells. Myeloid development, in contrast, is not obviously 
affected by the loss of Bcl11a. Bcl11a regulates expression of Bcl2, Bcl2-xL, and Mdm2, 
which inhibits p53 activities. Overexpression of Bcl2 and Mdm2, or p53 deficiency, rescues 
both lethality and proliferative defects in Bcl11a-deficient early B cells and enables the 
mutant CLPs to differentiate to lymphocytes. Bcl11a is therefore essential for lympho-
poiesis and negatively regulates p53 activities. Deletion of Bcl11a may represent a new  
approach for generating a mouse model that completely lacks an adaptive immune system.
© 2012 Yu et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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T cell development in the thymus can also be divided 
into several stages. The earliest thymocytes are double-
negative (DN) cells that do not express the two TCR co-
receptors, CD4 and CD8. Based on expression of c-Kit 
and/or CD44 and CD25, four DN subpopulations are de-
scribed (Ciofani and Zúñiga-Pflücker, 2007; Rothenberg 
et al., 2008): ETPs and DN2–4 (Fig. S1 D). ETPs are 
thought to be the earliest progenitors to seed in the thy-
mus and still retain non–T cell lineage differentiation po-
tential (Rothenberg et al., 2008). Almost all ETPs expressed 
Bcl11a (Fig. 1 B). DN2 thymocytes can be further divided 
into DN2a (c-Kithigh) and DN2b (c-Kitmid; Rothenberg et al., 
2008). T cell commitment is suggested to occur between 
DN2a and DN2b, and is marked by sharp up-regulation of 
Bcl11b, which is the paralogue of Bcl11a and essential for 
T cell commitment (Tydell et al., 2007; Ikawa et al., 2010; 
Li et al., 2010a,b). Although almost all DN2 thymocytes ex-
pressed Bcl11a (Fig. 1 B), in DN2b, Bcl11a expression levels 
(eGFP+) decreased drastically concomitant with the dramati-
cally increased Bcl11b expression (TdTomato+; Li et al., 2010b; 
Fig. 1 C). Therefore, high levels of Bcl11a expression mark 
uncommitted early thymocytes whereas high levels of Bcl11b 
define the committed thymocytes. Bcl11a expression levels 
further decreased in DN3–4 thymocytes and became un-
detectable in peripheral T cells (Fig. 1, B and C).
Distinct stages of NK cell development in the BM have 
been described in recent years (Di Santo, 2006; Carotta 
et al., 2011; Fathman et al., 2011). Although Bcl11a ex-
pression is undetectable in mature BM NK cells (Fig. 1 B), 
one fraction of the earliest NK progenitors (prepro–NKa), 
and NK progenitors (CD122+CD3NK1.1) clearly expressed 
Bcl11a (Fig. 1 B; Fig. S1 E). Nevertheless, the other subset 
of prepro–NK cells, prepro–NKb, did not. Bcl11a expression 
thus distinguishes the two prepro–NK cell subsets, which ap-
pear to be phenotypically and functionally similar (Carotta 
et al., 2011).
Expression of Bcl11a in hematopoietic lineages was fur-
ther determined by qRT-PCR analysis, which showed that 
Bcl11a was highly expressed in the HSC compartment 
(LinSca1+c-Kit+Flt3CD48CD150+) but the levels de-
creased in LMPPs (Fig.1 D). Both CLPs and B cells were 
highly enriched for Bcl11a expression, whereas T cells and 
NK cells had barely detectable Bcl11a expression. Expression 
of Bcl11a in CMPs, GMPs, and MEPs was low and further 
down-regulated in differentiated macrophages and granulo-
cytes (Fig. 1 D).
Deletion of Bcl11a in adult mice caused loss of early B cells 
and depletion of lymphoid progenitors
To investigate Bcl11a in adult hematopoiesis, we pro-
duced and analyzed the Bcl11a conditional knockout (cko) 
mice (Liu et al., 2003a). The cko mice were crossed to 
Rosa26-CreERT2 mice so that Bcl11a could be deleted in 
a tamoxifen (Tam)-inducible manner (Hameyer et al., 2007). 
Activation of Cre recombinase by Tam permits investigation 
of the immediate consequences of acute loss of Bcl11a. 
2007; Greig et al., 2010; Kosan et al., 2010; Jiang et al., 2011). 
Similar to B cells, thymocyte development in the thymus can 
be divided into several stages, but requires a combination of 
transcription regulators including Notch1, Gata3, Bcl11b, 
Tcf1, and Lyl-1 (Liu et al., 2010; Rothenberg et al., 2010; 
Weber et al., 2011; Zohren et al., 2012).
Bcl11a encodes a C2H2 zinc finger transcription factor 
that was initially discovered as a retroviral insertion site 
(Evi9) in myeloid leukemia tumors in the BXH-2 mouse 
(Nakamura et al., 1996, 2000), and was subsequently found 
to be overexpressed in some B cell lymphomas caused by 
chromosomal translocations (Satterwhite et al., 2001). We 
previously found that a Bcl11a germline-null allele caused 
neonatal lethality in the homozygous mutant, and identified 
its essential role in fetal lymphocyte development with a 
complete absence of B cells in the fetal liver and abnormal 
T cell development in the fetal thymus (Liu et al., 2003b). 
Recent studies have implicated that Bcl11a is a potential 
target of E2A, Ebf1, and Foxo1, which links Bcl11a into the 
common B cell transcription regulation framework (Doulatov 
et al., 2010; Lin et al., 2010; Treiber et al., 2010). We thus aimed 
to investigate whether Bcl11a is required in adult lympho-
cyte development.
RESULTS
Bcl11a is expressed in both hematopoietic  
progenitors and differentiated cells
We determined Bcl11a expression at the single-cell level by 
making and analyzing an eGFP reporter mouse where an 
IRES-eGFP-FRT-Neo-FRT cassette was targeted to the 3UTR 
of the Bcl11a locus (Fig. 1 A). The homozygous Bcl11aeGFP/eGFP 
mice had normal hematopoiesis and were used for detection 
of Bcl11a expression (GFP+) by flow cytometry.
GFP+ cells were detected in almost all Lin BM cells, in-
cluding HSCs, MPPs, LMPPs, CLPs, common myeloid pro-
genitors (CMPs), granulocyte-monocyte progenitors (GMPs), 
MEPs, monocyte-dendritic precursors, and common den-
dritic precursors (CDPs; Fig. 1 B and Fig. S1 A). Bcl11a 
expression was also detected in erythroid progenitors (EPs), 
differentiated macrophages, granulocytes and megakaryocytes, 
and at high levels in plasmacytoid DCs and conventional DCs 
(Fig. 1 B and Fig. S1 B).
B cell development from CLPs can be divided into 
several stages based on expression of cell surface markers 
and intracellular molecules (Hardy et al., 1991; Inlay et al., 
2009). CLPs are a heterogeneous population of cells that 
can be divided into all-lymphoid progenitor and B cell–
committed cells based on Ly6d expression (Inlay et al., 
2009; Mansson et al., 2010). Bcl11a is expressed in all CLPs 
(Fig. 1 B), suggesting a possible role for Bcl11a in both 
B lineage cells and progenitors primed for T and NK cells. 
Bcl11a expression remains high in pro–B and starts to be 
down-regulated in pre–B and immature B cells (Fig. 1 B). 
Spleen B cells, including transitional (Trans), mature (Mat), 
follicular (FO), and marginal zone (MZ) B cells, also expressed 
Bcl11a (Fig. 1 B; Fig. S1 C).
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help exclude the potential phenotypes caused by Cre tox-
icity. The flox/flox mice usually died in 10–14 d upon Tam 
treatment, likely because of the functions of Bcl11a in non-
hematopoeitic tissues (John et al., 2012). We thus analyzed 
lymphocyte development 1 wk after Tam administration. 
The CreERT2; Bcl11aflox/flox mice (referred to as flox/flox in 
this work) were grossly normal and fertile.
To delete Bcl11a in vivo, we treated 6–8-wk-old flox/flox 
and the control mice (CreERT2; Bcl11a+/+ or CreERT2; 
Bcl11a+/flox) with Tam. The use of control mice would 
Figure 1. Dynamic expression patterns of Bcl11a in hematopoiesis. (A) Schematic diagram of the Bcl11a-eGFP reporter allele. The eGFP reporter 
cassette flanked by two F3 sites is introduced to the 3UTR region of Bcl11a, 8 bp after the stop codon TAG. (B) Flow cytometry tracking Bcl11a expres-
sion using the Bcl11aeGFP/eGFP reporter mice. Cell surface markers for defining these cells are described in Table S1. (C) Expression of Bcl11a (eGFP+)  
and Bcl11b (Tdtomato+) in double negative (DN) thymocytes was measured by flow cytometry. DN thymocytes are identified as described in Fig. S1 D.  
(D) qRT-PCR analysis of Bcl11a expression in sorted hematopoietic populations. Data represent mean values of three independent biological replicates 
and all values are normalized to the expression of the Gapdh gene. Error bars indicate the SD. Thy, thymus; PB, peripheral blood; M, macrophages;  
G, granulocytes; Mk, megakaryocytes; B, BM CD19+ B cells; T, spleen CD3+T cells. In all flow cytometry assays, at least four mice were analyzed for each cell 
type in independent experiments.
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cells and pre–B cells were affected the most, with few pre-
senting in the flox/flox BM. Immature B cells reduced to 
approximately one-fifth of the wild-type number. How-
ever, within the experiment time window, B cells in the 
spleen, lymph node, and peripheral blood were not obvi-
ously reduced, indicating less dependency of these cells on 
Bcl11a (unpublished data). In contrast to B cells, other 
Genotyping of BM cells showed clean deletion of Bcl11a 
(Fig. S2 A), which was confirmed by nondetectable Bcl11a 
protein (Fig. S2 B). We first investigated B cell development 
in the BM. Flow cytometry analysis revealed severe de-
fects in the B cell compartment with the total BM B cell 
numbers in the flox/flox mice being reduced to 30% of 
those in the wild-type control mice (Fig. 2, A and B). Pro–B 
Figure 2. Profound defects of lymphoid development in Bcl11a-deficient adult mouse. B and T cells at different developmental stages were ana-
lyzed in the BM or thymus 1 wk after the mice were injected with Tam (n = 4/genotype, and the experiment was repeated 4 times). (A) BM B cells. Num-
bers refer to percentages of B cells in total BM-nucleated cells. (B) Cellularity of BM B cells in mice of the indicated genotypes. Cells were collected from 
two femurs of each mouse. (C) Thymocytes of various development stages. Lin thymocytes were further analyzed by expression of c-Kit and CD25 for 
DN thymocytes. (D) Cellularity of DN thymocytes in mice of indicated genotypes. (E) Analysis of LSKs, LMPPs, CLPs, and Ly6d+CLPs. Numbers refer to per-
centages of progenitors in total BM-nucleated cells. (F) Total cell numbers. +/+, CreERT2; Bcl11a+/+. +/flox, CreERT2; Bcl11a+/flox. flox/flox, CreERT2; 
Bcl11aflox/flox. *, P < 0.05; **, P < 0.01.
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of Bcl11a-deficient early B cells and thymocytes indicate that 
these cells either gradually differentiated or died and that they 
were not replenished from lymphoid progenitors. Addition-
ally, Bcl11a deletion depleted all NK progenitors, and only 
few NK cells were present in the BM (Fig. 3, C and D).
The BM chimeras also allowed us to examine the de-
fects in lymphoid progenitors 4 wk after Bcl11a deletion, 
and again more severe phenotypes were found: essentially 
no CLPs could be detected, and both the cell numbers and 
frequencies of LMPPs and LSKs were significantly reduced 
in the recipients engrafted with flox/flox BM cells (Fig. 3 E). 
We subsequently harvested donor CD45.1 BM cells from 
the Tam-treated primary recipients (1 mo of age), and 
transplanted them into irradiated secondary recipients. The 
secondary recipients had myeloid cells, erythrocytes, and 
megakaryocytes derived from the donor BM cells, but no 
B cells, T cells, or NK cells if the donor BM cells were of 
the flox/flox genotype (unpublished data).
After Bcl11a deletion, complete loss of lymphoid progen-
itors such as CLPs over time suggests that these progenitors 
had undergone apoptosis or differentiation and/or no new 
CLPs were derived from the LMPPs, or even HSCs. The 
substantial reduction of cell numbers in LMPPs or LSKs re-
flects the possible defective lymphoid development potential 
in Bcl11a-deficient LMPPs or HSCs.
Bcl11a is required for survival of early B cells
To investigate the cellular mechanism of the lymphopoie-
sis defects caused by Bcl11a deficiency, we first explored 
the possibility that Bcl11a deletion might cause apoptosis 
in developing lymphocytes or progenitors. To this end, we 
measured apoptosis in BM B cells of the flox/flox mice 4–5 d 
after Tam administration to capture the immediate conse-
quence of Bcl11a deletion. Dramatically increased apop-
tosis was observed in pro–B, pre–B, and immature B cells 
(Fig. 4 A). Bcl11a, thus, has a direct and essential role in 
committed B cells.
To experimentally confirm the apoptosis in early B cells 
in vitro, we cultured BM pro–B cells (CD43+CD19+). Once 
the cells reached confluence (1 wk), Tam was added to the 
culture to induce Bcl11a deletion, which led to rapid loss 
of Bcl11a protein (Fig. 4 B). Concomitant with the decrease 
of Bcl11a protein, the cultured B cells became apoptotic 
(Fig. 4 C). Indeed, within 4 d of Tam treatment, no live 
B cells could be found in the culture (Fig. 4 D), confirm-
ing the essential role of Bcl11a in these cells. We subse-
quently performed an in vitro pre–B cell assay to examine 
the requirement of Bcl11a in pre–B cells. No pre–B cells 
colonies were obtained from Bcl11a-deficient BM cells, again 
revealing the essential role of Bcl11a in these cells (unpub-
lished data).
Apoptosis in Bcl11a-deficient pro–B cells  
is rescued by exogenous Bcl2
Bcl2 is an important antiapoptotic factor. Once Bcl11a is de-
leted in cultured B cells, the Bcl2 protein levels were rapidly 
hematopoietic lineages in the BM, including T cells, NK 
cells, macrophages and granulocytes, and EPs, were not 
obviously affected (unpublished data).
In addition to the absence of B cells in the Bcl11a mu-
tant fetal liver, Bcl11a germline-null mutation also resulted 
in defective fetal thymocyte development (Liu et al., 2003b). 
1 wk after Tam treatment, the flox/flox thymus had few ETP 
cells and DN2 thymocytes (Fig. 2, C and D). However, the 
numbers of DN3 and DN4 thymocytes, as well as CD4+CD8+ 
double-positive (DP) and CD4+ or CD8+ single-positive thy-
mocytes, were not substantially changed (Fig. 2, C and D, 
and not depicted).
Because Bcl11a was also highly expressed in lymphoid 
progenitors (Fig. 1, B and D), we further investigated the 
effect of Bcl11a deletion in the progenitor compartments. 
The flox/flox mice had no Ly6d+ CLPs and a sevenfold re-
duction of total CLPs (Fig. 2, E and F). Moreover, signifi-
cantly reduced frequencies and numbers of LSKs and LMPPs 
were also revealed in the flox/flox mice (Fig. 2, E and F). In 
contrast to the defects in lymphoid progenitors, CMPs, 
GMPs, and MEPs were not obviously affected (unpublished 
data). These results suggest that, in the adult mouse, acute 
loss of Bcl11a causes lymphoid-specific defects and that 
Bcl11a has functions in both developing lymphocytes and 
lymphoid progenitors.
In addition to the severe lymphopoiesis defects caused by 
acute loss of Bcl11a in the conditional knockout mouse, loss 
of one copy of Bcl11a in the heterozygous mutant mice (±) 
that carry the null allele of Bcl11a (Liu et al., 2003b) also af-
fected lymphopoiesis. Compared with the wild-type control, 
the heterozygous mutants had 50% of LMPPs, CLPs, ETPs, 
and DN2 thymocytes (unpublished data), demonstrating a 
dose-dependent requirement for Bcl11a in lymphoid pro-
genitors and in lymphocyte development.
Complete loss of lymphoid development caused  
by Bcl11a deficiency is cell autonomous
We next investigated whether the defects in lymphoid lin-
eages caused by Bcl11a deficiency were cell autonomous, and 
whether a relatively longer time window (>1 wk) would re-
veal more profound phenotypes. We intravenously injected 
Lin BM cells from flox/flox and control mice into lethally 
irradiated CD45.1+ C57B6 recipients. The recipients were 
allowed 6–8 wk for engraftment before Tam administration, 
and the BM chimeras were subsequently harvested for analy-
sis either 1 or 4 wk later.
Compared with the Tam-treated flox/flox mice described 
above, the flox/flox BM chimeras exhibited similar lymphoid 
defects when cells were analyzed 1 wk after Tam treatment 
(unpublished data). However, 4 wk after Tam administration, 
more severe lymphoid defects were revealed: no pro–B, pre–B, 
or immature B cells could be detected, and the total BM 
B cells decreased to 5% of the wild-type (Fig. 3 A). There were 
also few ETPs or DN2 thymocytes (Fig. 3 B). The longer 
time window after Bcl11a deletion also revealed a drastic de-
crease of DN3 and DN4 thymocytes. The complete depletion 
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(all coexpressing GFP). Apoptosis in the GFP+ pro–B cells 
was blocked by the expression of these antiapoptotic factors 
(Fig. 4 F and not depicted).
E2A, Ebf1, and Pax5 work in concert to guide B cell de-
velopment. E2A and Ebf1 are considered to be competence 
decreased, as detected in flow cytometry (Fig. 4 E). We next 
explored whether expressing exogenous Bcl2 or other anti-
apoptotic factors in Bcl11a-deficient B cells might be able to 
rescue them from apoptosis. We infected the cultured B cells 
with retrovirus expressing either Bcl2, Bcl-xL (Bcl2l1), or Mcl1 
Figure 3. Severe defects in B, T, and NK cell precursors and lymphoid progenitor compartments in recipient mice engrafted with Lin BM cells 
(CD45.1). Lethally irradiated recipient mice (CD45.1+) engrafted with BM cells of indicated genotypes were treated with Tam and analyzed 4 wk later  
(n = 4/group, and the experiment was repeated 4 times). Panels show total cell numbers (bar graphs) and/or flow cytometry dot plots of donor BM  
B cells (A), donor thymocytes (B), donor BM NK cells (C and D), and donor lymphoid progenitors (E). Numbers in the flow cytometry plots refer to percent-
ages of gated cells in total donor nucleated BM cells or thymocytes. *, P < 0.05; **, P < 0.01.
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Figure 4. Apoptosis in Bcl11a-deficient B cell precursors could be rescued by exogenous Bcl2. (A) Apoptosis was measured by flow cytometry in 
Bcl11a-deficient early B cells in the BM. Numbers in histograms are percentages of the indicated gates. (B) Western blot analysis of Bcl11a protein at indi-
cated time points after Tam treatment. (C) Apoptosis in pro–B cells (IMDM supplemented with 50 ng/ml of IL-7, Flt3L, and SCF) after Bcl11a deletion detected 
by Annexin V and 7-AAD. Numbers in the flow cytometry plots refer to percentages of gated cells. (D) 1 million cultured pro–B cells were treated with Tam for 
4 d, and live cells were enumerated at indicated time points. (E) Detection of intracellular Bcl2 in cultured pro–B cells at indicated time points after Tam treat-
ment. (F) Apoptosis in cultured pro–B cells infected with retrovirus-expressing Bcl2. GFP+ cells (infected) were gated for analysis. An empty retroviral vector 
expressing GFP was used as the control. (G) qRT-PCR analysis of key lymphoid genes in cultured Bcl11a-deficient pro–B cells. Data represent mean values of 
three independent biological replicates and all values are normalized to Gapdh expression. Error bars indicate the SD. (H) Two-way hierarchical clustering of 
expression of 100 important lymphoid genes (Table S4) in cultured pro–B cells. Expression of these genes in wild-type DN3 thymocytes was used as an  
expression control. Scale indicates the log2 value of normalized signal level. For A, C, D, E, F, and G, data represent at least three independent experiments.
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and Bcl2 were coexpressed (Bcl2/Mdm2; flox/flox). The res-
cue by Bcl2/Mdm2 was also revealed by the increased cell 
numbers in the culture (Fig. 5 B).
Genetic interaction of Bcl11a and p53 in lymphopoiesis
Although Bcl2/Mdm2 coexpression was able to rescue cul-
tured pro–B cells from apoptosis and cell cycle defects, com-
pared with the wild-type control cells where 35% of cells 
were in S phase, the rescued B cells still had only 4–5% of 
cells in S phase and proliferated slowly (Fig. 5, A and B). To 
further dissect the genetic interaction between Bcl11a and 
the p53 pathway, we crossed the flox/flox mice to p53 con-
ditional knockout mice (Jonkers et al., 2001) to produce 
Rosa26CreERT2; Bcl11aflox/flox/p53flox/flox mice (referred to as 
Dflox/flox). We first cultured BM cells from the Dflox/flox 
mice in B cell media to obtain pro–B cells, and then deleted 
both Bcl11a and p53, which led to the absence of both pro-
teins (Fig. S2 C). Deleting p53 enabled 20–25% of Bcl11a-
deficient pro–B cells to be in S phase, which also proliferated 
robustly (Fig. 5, A and B).
The in vitro rescue of Bcl11a-deficient B cells by p53 de-
ficiency led us to examine the genetic interaction of Bcl11a 
and p53 in vivo. We treated Dflox/flox mice with Tam and 
harvested BM cells 5 d later. Efficient deletion of both Bcl11a 
and p53 was obtained at this time (Fig. S2 D). Flow cytome-
try and cell number analysis demonstrated a significant in-
crease of pro–B, pre–B, and immature B cells in the Dflox/flox 
mice compared with those in the flox/flox mice (Fig. 5 D), 
indicating that p53 deficiency was indeed able to rescue early 
B cell development.
Over time, Bcl11a deletion caused complete loss of 
CLPs and reduced cellularity of LMPPs and LSKs (Fig. 3 E). 
We next examined whether p53 deficiency could also help 
Bcl11a-deficient lymphoid progenitors. 5 d after Bcl11a dele-
tion, more CLPs and Ly6d+CLPs were found in Dflox/flox 
mice (Fig. 5 E). However, surprisingly, p53 deficiency did not 
appear to help LSKs or LMPPs as their numbers were not in-
creased (Fig. 5 E). It is possible that Bcl11a-deficient early 
lymphoid progenitors such as LSKs and LMPPs require 
additional rescue mechanisms apart from p53 deficiency.
To further study the genetic interaction of Bcl11a and p53 
in lymphoid development, we made BM chimeras from BM 
cells of Dflox/flox mice. The BM chimeras would allow us to 
investigate the phenotypes of loss of Bcl11a and p53 over a 
longer period of time, and to assess cell autonomous pheno-
types, specifically in hematopoietic lineages. The recipient mice 
were allowed 6–8 wk for donor cell engraftment, and were an-
alyzed 4 wk after Tam treatment. Surprisingly, unlike the pres-
ence of pro–B, pre–B, and immature B cells in Dflox/flox mice 
5 d after Tam treatment, the BM chimeras now had few early 
B cells, and the total B cell numbers from donor BM cells 
were also drastically decreased (Fig. 6 A). Strikingly, all CLPs 
were depleted with decreases of LMPPs and LSKs (Fig. 6 B).
To test whether the CLPs presented in Dflox/flox mice 
shortly after Tam treatment were alive and functional, we 
isolated CLPs 4–5 d after Tam treatment, and cultured them 
and specification factors, respectively, whereas Pax5 acts as 
a commitment factor for B cell identity. Indeed, overex-
pression of Ebf1 can rescue defective B cell development 
caused by loss of Ikaros, E2A, and Runx1 (Seet et al., 
2004; Reynaud et al., 2008; Seo et al., 2012). We thus 
used retrovirus expressing E2A (both E12 and E47), Ebf1, 
Pax5, and Stat5CA (constitutively active form). None of 
these key B cell genes was able to rescue the Bcl11a-deficient 
pro–B cells, as GFP+ cells were still apoptotic and the culture 
eventually did not have live cells (unpublished data). The res-
cue of Bcl11a-deficient B cells by Bcl2, but not by the core 
B cell genes, demonstrates that Bcl11a functions distinctly 
and is normally required for cell survival in B cell develop-
ment. Not surprisingly, deletion of Bcl11a did not signifi-
cantly change the expression of E2A (Tcf3), Ebf1, or Pax5 
in B cells (Fig. 4 G).
We subsequently performed global gene expression of 
Bcl2-rescued, Bcl11a-deficient cultured pro–B cells and 
compared it to that of the wild-type control B cells. Nei-
ther substantial decrease of key B cell genes nor increase 
of key genes for T or myeloid lineages such as Bcl11b and 
Cebpa was detected in the rescued B cells (Fig. 4, G and H; 
Table S4), indicating that Bcl11a-deficient B cells retained 
their B cell identity and were not converted to another 
cell type. Therefore, unlike Bcl11b (in regard to maintain-
ing T cell identity; Li et al., 2010b), Bcl11a is not required 
to maintain B cell identity in the committed B cells and 
likely plays a general, permissive role in these cells. This is 
consistent with the fact that Bcl11a is expressed in most 
hematopoietic cells.
Coexpression of Mdm2 and Bcl2 rescues both apoptotic  
and proliferative defects in Bcl11a-deficient pro–B cells
Although overexpression of Bcl2, Bcl-xL, or Mcl1 efficiently 
rescued Bcl11a-deficient B cells from apoptosis, these B cells 
appeared to be in senescence because no cells were in S phase 
(Bcl2; flox/flox in Fig. 5 A), and the cell numbers in the cul-
ture did not increase over 6 d (Fig. 5 B). Consistent with a 
cell cycle defect, expression of the cyclin-dependent kinase 
inhibitor p21 (also known as Cdkn1a, p21WAF1/Cip1), 
but not of p27 (Cdkn1b) or p57 (Cdkn1c), was up-regulated 
in Bcl2; flox/flox B cells (Fig. 5 C). p21 promotes cell cycle 
arrest in response to many stimuli, and is induced by p53 
(Abbas and Dutta, 2009). To further investigate the effect 
of Bcl11a deletion on the p53 pathway, we performed West-
ern blot analysis of p53 and Mdm2 in Bcl11a-deficient BM 
B cells. Bcl11a deletion resulted in barely detectable Mdm2 
and accumulation of p53 (Fig. S2 C). Mdm2 inhibits p53 tran-
scriptional activity, favors its nuclear export, and stimulates its 
degradation (Wade et al., 2010; Vucic et al., 2011). Lower levels 
of Mdm2 cause lymphopoiesis defects (Mendrysa et al., 2003). 
The apoptosis and cell cycle defect in Bcl11a-deficient B cells 
might be caused by the aberrant Mdm2–p53–p21 pathway, 
and therefore, overexpressing Mdm2 together with Bcl2 should 
relieve the cell cycle block. As shown in Fig. 5 A, 4–5% of 
Bcl11a-deficient B cells were in S phase when exogenous Mdm2 
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Complete loss of lymphoid development  
potential in Bcl11a-deficient LSKs
To investigate whether Bcl11a-deficient LSKs lost the ability 
to produce any lymphoid progenitors or lymphocytes and to 
test the function of LSKs with both Bcl11a and p53 defi-
ciency in lymphoid development, we purified LSKs from the 
Tam-treated flox/flox, Dflox/flox, or control mice and cultured 
them on OP9 stromal cells. B cells were cultured out only 
from the wild-type LSKs, but not from the flox/flox or Dflox/
flox LSKs (unpublished data), confirming that LSKs of both 
flox/flox and Dflox/flox were defective in lymphoid devel-
opment potential. We next injected purified LSKs (from 
on OP9 stromal cells in the presence of IL7, SCF, and Flt3L. 
B cells were cultured out from CLPs of Dflox/flox and the 
wild-type control mice, but not from CLPs of the flox/flox 
mice (Fig. 6 C). Therefore, p53 deficiency was able to rescue 
the developing B cells and CLPs. The fact that the rescued 
early lymphoid precursors or progenitors were eventually 
depleted over time suggests that no fresh progenitors are 
produced from LSKs. These results also demonstrate that 
in developing B cells and CLPs, Bcl11a primarily functions 
for survival and proliferation through regulating the p53 
pathway, and thus likely plays a permissive role similar to 
IL-7R in T cells (Maraskovsky et al., 1997).
Figure 5. Genetic interaction of Bcl11a 
and p53 in lymphoid development. (A) Cell 
cycle of cultured pro–B cells infected with 
retrovirus expressing Bcl2 and/or Mdm2 was 
analyzed by Edu/7-AAD staining. (B) 3 d after 
Tam treatment, 1 million pro–B cells were 
cultured and counted daily for viability.  
(C) qRT-PCR analysis of p21, p27, and p57 in 
Bcl11a-deficient pro–B cells infected with the 
Bcl2-expressing retrovirus. (D and E) Presence 
of pro–B, pre–B, and immature B cells (D), or 
lymphoid progenitors (E), in BM of Dflox/flox 
mice 5 d after Tam treatment. Numbers refer 
to percentages of gated cells in total donor 
nucleated BM cells. Data in A, B, C, D, and E 
represent at least three independent experi-
ments. *, P < 0.05; **, P < 0.01.
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underwent apoptosis. Similar to rescue of apoptosis of early 
B cells by Bcl2/Mdm2, p53 deficiency essentially rescued 
apoptosis in LSKs, HSCs, LMPPs, and CLPs (green line in 
Fig. 7 C). Rescue of Bcl11a-deficient CLPs from apoptosis by 
p53 deficiency enables CLPs of the Dflox/flox mice to survive 
and to differentiate to lymphocytes (Fig. 6 C). Nevertheless, 
LSKs and LMPPs of the Dflox/flox mice were not rescued 
either in cell number or lymphoid development potential.
Deletion of Bcl11a caused increased p21 expression and 
cell cycle defects in early B cells (Fig. 5 C). We next investi-
gated whether p21 expression was changed by p53 deficiency 
in HSCs of Dflox/flox mice. p53 deficiency indeed reduced 
p21 expression to the wild-type level, whereas p27 was 
slightly decreased and p57 was slightly increased (Fig. 7 D), 
suggesting that cell cycle defects were unlikely to cause lym-
phoid development defects in Bcl11a-deficient LSKs or HSCs 
and that Bcl11a functions by another mechanism.
Several transcription factors, such as Pbx1, Runx1, Ikzf1 
(Ikaros), Sfpi1 (Pu.1), Tcf3 (E2A), and Foxo1, are required for 
the early stages of lymphoid development. In HSCs, Pbx1 
showed significant decrease when Bcl11a was deleted (Fig. 7 E). 
Pbx1 is reported to regulate self-renewal of long-term HSCs 
by maintaining their quiescence (Ficara et al., 2008), and is 
required for generation of CLPs (Sanyal et al., 2007). How-
ever, lower Pbx1 is probably not the cause of complete loss of 
lymphoid potential, as Pbx1/ stem cells can produce T cells 
Tam-treated mice) with CD45.1+ helper BM cells into re-
cipients and examined their in vivo differentiation poten-
tial to exclude the possibility that Dflox/flox LSKs may 
require the BM microenvironment for proper proliferation 
and/or differentiation.
6–8 wk after engraftment, the recipients were analyzed. As 
shown in Fig. 7, A and B, LSKs of flox/flox and Dflox/flox 
mice did not produce any CLPs in the BM or ETPs in the thy-
mus, which led to an absence of B, T, and NK cells in the BM 
or the thymus (Fig. 7, A and B), whereas myeloid progenitors 
were not noticeably changed (unpublished data). The absence 
of mature lymphocytes from donor LSKs also excluded the 
possibility that the lymphoid progenitors were initially gener-
ated, but subsequently differentiated and thus depleted.
In addition to a complete lack of lymphocytes and CLPs, 
a significant or substantial reduction of the LSKs, HSCs, and 
LMPPs was found in the recipients of the flox/flox and Dflox/
flox LSK donors (Fig. 7 A). These results thus demonstrate that 
deletion of Bcl11a specifically abolishes lymphoid develop-
ment potential in hematopoietic progenitors and that p53 
deficiency is not sufficient to rescue this early defect.
We next explored what caused the reduced cell numbers 
in the LSK compartment and examined apoptosis in these 
cells. As shown in Fig. 7 C, many LSK, HSC, and LMPP 
compartment cells went through apoptosis once Bcl11a was 
deleted (red line in Fig. 7 C). Bcl11a-deficient CLPs also 
Figure 6. p53 deficiency did not rescue 
long-term B cell development or lymphoid 
progenitor defects. Lethally irradiated recipi-
ent mice (CD45.1+) were transplanted with 
Lin BM cells (CD45.1) and were treated 
with Tam to delete Bcl11a. Recipients were 
subsequently analyzed 4 wk later (n = 4/geno-
type). (A) Total cell numbers of donor BM  
B cells of indicated genotypes. (B) Total  
numbers of donor LSKs, LMPPs, and CLPs.  
(C) Freshly sorted CLPs (5,000) from mice of 
indicated genotypes 3 d after Tam treatment 
were cultured on OP9 stromal cells in the 
presence of 10 ng/ml of IL-7 and Flt3L for  
14 d. A–C represent at least three indepen-
dent experiments. *, P < 0.05; **, P < 0.01.
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Figure 7. Loss of lymphoid development potential in LSKs of flox/flox and Dflox/flox mice. Flow cytometric–sorted LSKs from Tam-treated mice 
were transplanted to recipients with helper BM cells. Donor cells (CD45.1) were analyzed 8 wk after transplantation. (A) Total numbers of donor LSK, 
HSC, LMPP, CLP and ETP of indicated genotypes. (B) Populations of B, T, and NK cells analyzed by flow cytometry. Numbers indicate percentages of lym-
phocytes in total BM-nucleated cells. (C) Apoptosis in Bcl11a-deficient stem cells or progenitors (red line) analyzed by Annexin V staining. Apoptosis in 
these cells were rescued by p53 deficiency (green line). BM cells were harvested and stained 4 d after Tam treatment. (D and E) qRT-PCR analysis of cell 
cycle, lymphoid, and myeloid genes in freshly sorted HSCs. (F) qRT-PCR analysis of lymphoid and myeloid genes in LMPPs. Data represent mean values of 
three independent biological replicates and all values are normalized to Gapdh expression. Error bars indicate the SD. A–F represent at least three inde-
pendent experiments. *, P < 0.05; **, P < 0.01.
(Sanyal et al., 2007). Besides, Pbx1, Runx1, and Foxo1 were also 
down-regulated. In contrast, the myeloid gene myeloperoxi-
dase (Mpo) was significantly up-regulated (Fig. 7 E). Gata1 
and Klf1 are critical for megakaryocyte/erythroid develop-
ment (Iwasaki et al., 2003; Siatecka and Bieker, 2011). Klf1 is 
reported to regulate Bcl11a (Zhou et al., 2010). Once Bcl11a 
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was not changed (Fig. 7 F). Bcl11a therefore has essential func-
tions in the early hematopoietic progenitors that are distinct 
from that of Pu.1, Ikaros, E2A, and Mef2c.
Similar to that in HSCs, expression of Mpo, together with 
Cebpa, was up-regulated in Bcl11a-deficient LMPPs (Fig. 7 F). 
LSKs of the flox/flox or Dflox/flox mice, however, did not 
produce more myeloid cells to fill in the space of the depleted 
lymphoid compartments (unpublished data). The inability of p53 
deficiency to restore lymphoid potential in Bcl11a-deficient 
LMPPs is therefore reflected on the fact that deletion of 
p53 did not substantially change the expression patterns of 
the key lymphoid genes in these progenitors.
Genome-wide analysis of Bcl11a binding sites  
identifying downstream target gene candidates
Bcl11a is a zinc finger transcription factor that binds to its 
target sites in the genome (Avram et al., 2002; Liu et al., 2006). 
The aforementioned genetic studies indicate that Bcl11a 
regulates p53 via Mdm2 or Mdm4 in lymphocyte develop-
ment. To confirm this regulation, we performed chromatin 
immunoprecipitation (ChIP) in mouse B cells with an anti-
Bcl11a antibody. Bcl11a was reported to have a consensus 
was deleted, expression of both Gata1 and Klf1 was signifi-
cantly up-regulated in HSCs (Fig. 7 E), which surprisingly 
did not lead to increased MEPs (unpublished data). Consis-
tent with the inability of p53 deficiency to rescue lymphoid 
development from LSKs, expression levels of most of the ex-
amined genes, including Ikzf1, Sfpi1, Tcf3, and Foxo1, were 
not altered by p53 deficiency.
We also quantified expression of key lymphoid regula-
tors or markers in LMPPs (Fig. 7 F). Several of them had 
decreased expression in Bcl11a-deficient LMPPs, including 
Runx1, which interacts with Ebf1 to promote activation of 
B cell–specific genes (Lukin et al., 2010; Maier et al., 2004); 
Flt3, which marks LMPPs (Adolfsson et al., 2005); IL7R 
which is expressed in CLPs and is required for normal lym-
phocyte development (Peschon et al., 1994; von Freeden-Jeffry 
et al., 1995); Foxo1, which has distinct functions at various stages 
of B cell differentiation (Amin and Schlissel, 2008; Dengler 
et al., 2008); and Notch1, which is required for normal T cell 
development. However, expression of genes important in 
LMPPs, including Ikzf1, Sfpi1, and Tcf3, was not significantly 
altered. Similarly, expression of Mef2c, which regulates lym-
phoid versus myeloid fate choice (Stehling-Sun et al., 2009), 
Figure 8. Analysis of Bcl11a binding sites in mouse pro–B cells. (A) qPCR validation of Bcl11a binding at the Mdm2, Mdm4, and Bcl2 loci in ChIP assay. 
Potential Bcl11a binding sites (red boxes) at the Mdm2 and Mdm4 loci, predicted as GGCCGG-containing sequences. Black bars indicate the qPCR-amplified 
regions of the validated sites. Potential Bcl11a binding sites (arrows) at the mouse Bcl2 locus, predicted as homologous regions to BCL11A-binding sites at the 
human BCL2 locus (ENCODE project), are analyzed by ChIP assay. The fold-enrichments of the amplified regions are (from 5 to 3) are as follows: 1.31 ± 0.40, 
1.69 ± 0.32, 5.32 ± 0.92 (red arrow), 1.87 ± 0.001, 2.37 ± 0.60, 2.80 ± 0.43, 1.32 ± 0.21, 2.12 ± 0.44, 1.88 ± 0.21, 2.29 ± 0.40, 3.00 ± 0.16, and 2.68 ± 0.72.  
(B) Distribution of Bcl11a-binding sites in the genome from ChIP-Seq analysis. The 10-kb region upstream from transcription start site is defined as Proximal 
Promoter, and the 10-kb region downstream from transcription stop site is defined as downstream. (C) qPCR validation of Bcl11a binding at the genomic loci of 
Bcl-xL, p21, Pax5, and E2A. Genomic DNA pull-down using IgG was used as a control. A–C represent three independent experiments. *, P < 0.05; **, P < 0.01.
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Interestingly, in thymocyte development, Bcl11a is drasti-
cally down-regulated in DN2b cells, the earliest commit-
ted T cells, whereas Bcl11b is sharply up-regulated (Liu et al., 
2010; Rothenberg et al., 2010). Further investigation is 
needed to dissect the interaction between these two para-
logues in T cell commitment.
Genetic analysis demonstrates that Bcl11a has direct roles 
in developing lymphocytes. Bcl11a deletion causes apoptosis 
in early B cells both in vivo and in vitro. Once apoptosis is 
blocked by expressing exogenous Bcl2 or Bcl-xL, the rescued 
B cells express high levels of p21 and appear to be in G0/G1 
phase thus uncovering the proliferation defect in these cells. 
Both Mdm2 and Bcl2 are down-regulated in Bcl11a-deficient 
B cells. ChIP experiments indicate that Bcl11a binds Mdm2 
and Bcl2 loci. Coexpressing Mdm2 with Bcl2 rescues both 
apoptosis and proliferation defects caused by Bcl11a deficiency. 
Bcl11a deletion also leads to p53 accumulation in lympho-
cytes, likely caused by the decreased Mdm2/Mdm4. The 
genetic interaction of Bcl11a and p53 is further revealed by 
rescuing Bcl11a-deficient B cells and CLPs both in vitro and 
in vivo by p53 deficiency.
Bcl11a deletion also causes apoptosis in LMPPs and LSKs, 
which is rescued by p53 deficiency. Surprisingly, lymphoid 
potential is not restored, proving that Bcl11a has additional 
functions in these early progenitors besides regulating p53. 
The HSC compartment consists of heterogeneous popula-
tion of stem cells. Bcl11a expression in HSCs detected in the 
Bcl11a-eGFP reporter mouse does not have a bimodal pat-
tern, suggesting that either variations of Bcl11a expression in 
the lymphoid-primed stem cells, or progenitors might be rel-
atively small, or there exist posttranslational modifications of 
Bcl11a protein. Recent studies suggest that CD150low HSCs 
have both lymphoid and myeloid potential, whereas CD150high 
HSCs primarily produce myeloid cells even though they have 
higher self-renewal capability (Beerman et al., 2010; Morita 
et al., 2010). However, deletion of Bcl11a does not appear to 
cause noticeable difference between CD150high and CD150low 
HSCs (unpublished data). Several key regulators are known 
in lymphocyte development. Several of these genes, such 
as Pbx1, Runx1, Notch1, Flt3, Il7r, and Foxo1, are down-
regulated in Bcl11a-deficient HSCs or LMPPs. In contrast, 
the myeloid-specific gene Mpo, and two key genes in eryth-
rocyte/megakaryocyte development, Gata1 and Klf1, are 
up-regulated. However, their increased expression does not 
translate to increased CMPs, GMPs, or MEPs, indicating that 
the requirement for Bcl11a in either LMPPs or HSCs is not 
simply repressing the nonlymphoid lineages. It is more possi-
ble that deletion of Bcl11a may simply deplete all the lym-
phoid-primed or –biased stem cells. It will thus be necessary 
in the future investigation to perform single-cell analysis, 
combining with genetic studies, to further dissect the lym-
phoid developmental defects in the HSC compartment. It is 
worth noting that although we did not observe obvious my-
eloid development defects when Bcl11a was deleted, a more 
thorough investigation focusing on myeloid development 
and functions in the adult mouse is needed.
binding site as GGCCGG (Avram et al., 2002). Computa-
tional prediction indicated that there were several putative 
binding sites in the Mdm2 and Mdm4 loci (Fig. 8 A). Quantita-
tive real-time PCR (qPCR) of ChIP pull-down DNA showed 
a 4.95-fold enrichment using the Bcl11a antibody compared 
with the IgG control in the promoter region of Mdm4 locus. 
A 3.08-fold enrichment of Bcl11a binding was also found at 
the Mdm2 locus (Fig. 8 A). Bcl11a deletion caused rapid down-
regulation of Bcl2 in early B cells. Analysis of ENCODE (The 
Encyclopedia of DNA Elements) data shows that in human 
B lymphocytes, there are 15 putative Bcl11a binding sites at 
the human BCL2 intronic and downstream regions. We ana-
lyzed these genomic regions and found that 12 of them were 
conserved in the mouse (Fig. 8 A). qPCR results showed that 
a higher than twofold enrichment of Bcl11a binding was 
found at seven regions, with the highest fold enrichment 
(fivefold) being identified in an intronic region (Fig. 8 A).
To screen for more putative downstream target genes 
of Bcl11a in lymphocytes, we conducted ChIP followed by 
next generation DNA sequencing (ChIP-Seq) using mouse 
pro–B cell nuclear extract. A total of 34.2 million mappable 
reads were analyzed and 10,865 peaks were identified. The 
fraction of peaks with different genomic distribution was de-
termined, and majority of the peaks were located in inter-
genic, intronic, and promoter regions (Fig. 8 B). In total, 
Bcl11a may bind to 4,517 genomic loci, among which were 
E2A, Pax5, Bcl11b, and Bcl-xL. Potential binding sites of 
Bcl11a were also found at the p21 locus but not at p27 or 
p57. We next repeated the ChIP experiments followed by 
qPCR to validate several predicted ChIP-Seq peaks, and 
showed that Bcl11a strongly bound to the intronic region of 
Bcl-xL locus, which resulted in 95-fold enrichment in Bcl11a 
antibody pull-down DNA (Fig. 8 C). Other validated loci 
included p21, Pax5, and E2A loci. However, deletion of 
Bcl11a in B cells did not affect expression of Pax5 or E2A or 
other key B cell genes (Fig. 4, G and H). Therefore, although 
Bcl11a possibly participates in regulating Pax5 or E2A ex-
pression, these loci are mainly regulated by other mechanisms 
and Bcl11a is primarily involved in the survival and prolifera-
tion of developing early B cells.
DISCUSSION
Bcl11a is suggested to have multiple functions in normal he-
matopoiesis and leukemia (Nakamura et al., 2000; Satterwhite 
et al., 2001; Liu et al., 2003b; Yin et al., 2009). Deletion of 
Bcl11a causes absence of B cells in the fetal liver (Liu et al., 
2003b). Conversely, ectopic Bcl11a expression from chro-
mosomal translocations leads to B cell lymphomas in patients 
(Satterwhite et al., 2001). This study reveals the essential 
functions of Bcl11a in CLPs and developing lymphocytes, 
and uncovers the critical role of Bcl11a for lymphoid devel-
opmental potential in early hematopoietic progenitors.
During lymphocyte development, the expression of Bcl11a 
is found to be highly enriched in CLPs, ETPs, DN2 thymocytes, 
and B cells. These progenitors and early lymphocytes are 
completely lost when Bcl11a is deleted in the adult mouse. 
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of Bcl11a and a loxP site upstream of exon 4 of Bcl11a. Bcl11aeGFP/eGFP mice 
were generated on C57BL/6 background. The Bcl11aflox/flox mice were crossed 
to Cre-ERT2 mice to generate Cre-ERT2; Bcl11aflox/flox (flox/flox) mice. 
flox/flox, flox/+, Cre-ERT2, Bcl11a germline heterozygous mutant (+/), 
and the wild-type control mice were of a mixed C57BL/6 and 129S5 back-
ground. C57BL/6CD45.1+ mice were used as recipients for transplantation 
of BM cells or LSKs. All mice were 8–10 wk of age at the time of experi-
ments, and at least 4 mice of one genotype were used in each experiment. The 
primers used for genotyping were listed in Table S3. All mice used were from 
colonies maintained at RSF of the Sanger Institute. Housing and breeding of 
mice and experimental procedures were according to the UK 1986 Animals 
Scientific Procedure Act and local institute ethics committee regulations.
Antibodies. All antibodies used are described in Table S2.
Flow cytometry and cell sorting. Cells from BM (femoral bone), spleen, 
thymus, and lymph node were mechanically dissociated and the red blood 
cells were removed using ACK lysis buffer (Lonza). Blood was collected into 
EDTA tubes (Sarstedt). In vitro–cultured cells were collected and washed 
with PBS containing 2% FBS before antibody labeling. For all cells, Fc 
receptors were blocked with anti-CD16 (2.4G2) before antibody labeling. 
Cells were stained with specific combinations of antibodies (Table S2) on ice 
for 20 min before washing. Data acquisition was performed using Fortessa 
(BD) or LSRII (BD) with dead cells excluded based on scatter profile or 
propidium iodide inclusion. Analysis was performed using FlowJo (Tree 
Star) software. Sorting was performed using a MoFlo XDP (BD).
Determination of hematopoietic cell population size. The absolute 
numbers of viable cells of the BM (two femurs), spleen, thymus, lymph 
node, and peripheral blood were determined by Trypan blue exclusion. The 
absolute numbers of hematopoietic cells in an organ were calculated by the 
percentage of each sub-gate in the viable cell gate and the total cell numbers 
(propidium iodide–negative).
In vivo and in vitro apoptosis assays. For the in vivo assay, the flox/flox 
and control mice were treated with 4.0 mg Tam (Sigma-Aldrich) by intra-
peritoneal injection over three consecutive days. 5–7 d later, BM cells were 
collected from these treated mice and immediately stained with Annexin V 
and 7-AAD (BD) according to the manufacturer’s instructions for detection 
of apoptotic cells.
BM cells from the flox/flox and control mice were cultured in the pres-
ence of 50 ng/ml IL-7, 50 ng/ml Flt3L, and 50 ng/ml SCF for 7 d, followed 
by Tam administration (final concentration 0.1 µM) in the media to delete 
Bcl11a. Cells were collected at different time point for staining with Annexin V 
and 7-AAD (BD) according to the manufacturer’s instructions for detection 
of apoptotic cells.
BM chimeras. Single-cell suspensions of BM cells from the flox/flox, the 
Dflox/flox and the control (+/+ or +/flox) mice were injected intravenously 
into lethally irradiated (2 × 500 cGy) recipient mice (CD45.1+) for reconsti-
tution for 6–8 wk.
For HSC reconstitution in vivo, the LSK cells were purified from BM 
of the flox/flox, the Dflox/flox, and the control mice (+/+ or +/flox) treated 
with Tam for 4–5 d. The sorted LSK cells (2,000 cells) were injected with 
helper CD45.1+ BM cells (2 × 105 cells) into lethally irradiated (2 × 500 cGy) 
recipient mice (CD45.1+) via the tail vein.
In vitro culture assay for differentiation of LSKs. OP9 stromal cells 
were cultured in -MEM (Sigma-Aldrich) with 10% FCS, 1% penicil-
lin/streptomycin, and 2 mM l-glutamine (Life Technologies). Cells were 
passaged every 2–3 d by trypsinization (Invitrogen). A monolayer (70–80% 
confluent) of OP9 cells was prepared 24 h before co-culture. Sorted LSKs or 
sorted CLPs from flox/flox, Dflox/flox, and control (+/+) mice treated 
with Tam 4 d earlier were cultured for 14 d in the presence of for Flt3L 
(10 ng/ml; PeproTech) and IL-7 (10 ng/ml; PeproTech). After incubation, 
The p53 pathway is known to be critical for HSC self- 
renewal and quiescence (TeKippe et al., 2003; Liu et al., 2009), 
and Bcl11a is also implicated in HSCs (Kustikova et al., 2005). 
Unlike deleting p53 alone, loss of both p53 and Bcl11a does 
not lead to an expanded HSC compartment. In contrast, HSCs 
were substantially decreased, suggesting that Bcl11a is likely 
epistatic to p53 in HSCs. It was recently suggested in an in vitro 
system that p53 might negatively regulate Bcl11a (Jabbour 
et al., 2012). The complex interaction of Bcl11a and p53 in 
homeostasis of HSCs, including the target genes regulated by 
Bcl11a and p53, and the signals and factors that regulate these 
two genes, awaits further investigation. In addition to the p53 
pathway in this study, Bcl11a is known to be regulated by Klf1 
(Zhou et al., 2010), to interact with repressor complexes 
(Sankaran et al., 2008), to modulate chromosomal loop for-
mation (Xu et al., 2010) in erythrocytes, and to interact with 
COUP-TFs (Avram et al., 2000). These studies will eventually 
help dissect the molecular and cellular mechanisms of Bcl11a’s 
functions in HSCs or LSKs in lymphoid development.
The regulation of p53 by Mdm2 is also important in devel-
oping lymphocytes, as lower levels of Mdm2 induce apoptosis 
and proliferation defects (Mendrysa et al., 2003). In developing 
lymphocytes, Bcl11a acts to prevent p53 activities by directly 
regulating Bcl2, Bcl-xL, Mdm2, and Mdm4. Although ChIP-
Seq identifies several key lymphoid genes, such as Pax5 and 
E2A, to be Bcl11a’s potential downstream targets, their ex-
pression is not substantially altered in Bcl11a-deficient B cells 
or in Bcl2 rescued Bcl11a-deficient B cells, suggesting that their 
regulation by Bcl11a in B cells is not critical in these cells. On 
the other hand, the core B cell transcription factors Ebf1, Foxo1, 
and E2A bind the Bcl11a locus (Doulatov et al., 2010; Lin et al., 
2010; Treiber et al., 2010) and possibly regulate its expression 
for cell survival and proliferation in developing lymphocytes. 
Therefore, although Bcl11a functions differently from these 
core B cell development genes, it is still a key component of the 
transcription factor network in B cell development.
It was reported that human BCL11A occupies discrete 
binding sites in the -globin gene cluster in adult erythroid 
progenitors and executes its function as a transcription repres-
sor to control fetal-to-adult switch of hemoglobin expression 
(Xu et al., 2010). As revealed by ChIP-seq in B cells, the near-
est Bcl11a binding site to the mouse -globin cluster is 85 kb 
upstream of Hbb-y and 4 kb upstream of the mouse olfactory 
receptor gene MOR55. The lack of Bcl11a binding events 
at the -globin locus in B cells possibly reflects that Bcl11a 
occupies differential gene targets in different cell types.
In summary, we have identified Bcl11a as an essential 
transcription factor in lymphoid development. Bcl11a is re-
quired for the survival and proliferation of early B cells and 
CLPs by suppressing the p53 pathway, and has additional es-
sential functions in LMPPs and HSCs for lymphoid develop-
ment, which warrants further characterization.
MATERIALS AND METHODS
Mice. Bcl11a-eGFP reporter allele was generated by introducing a loxP-F3-
IRES-eGFP-polyA-F3-FRT-PGK-E7-Neo-polyA-FRT cassette into the 3UTR 
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Table S1 gives definitions of the hematopoietic populations. Table S2 lists 
the antibodies used in this study. Table S3 has the primer information in this 
study. Table S4 lists the 100 lymphoid genes chosen for performing cluster-
ing analysis. Online supplemental material is available at http://www.jem 
.org/cgi/content/full/jem.20121846/DC1.
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